![Akintunde Bello](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Akintunde Bello
Direktor/Vorstandsmitglied bei
XILIO THERAPEUTICS, INC.
Profil
Akintunde Bello is currently Director at Xilio Therapeutics, Inc. since 2025.
Formerly, Dr. Bello was SVP, Head-Pharmacology & Bioanalysis at Bristol Myers Squibb Co. Education includes a doctorate from King's College London, a graduate degree from The University of Manchester, and an undergraduate degree from the University of Portsmouth.
Aktive Positionen von Akintunde Bello
| Unternehmen | Position | Beginn |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.06.2025 |
Ehemalige bekannte Positionen von Akintunde Bello
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2025 |
Ausbildung von Akintunde Bello
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
17
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Portsmouth
 University of Portsmouth Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
